Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2019-06-12
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to evaluate the clinical efficacy and safety of two
oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with
moderate-to-severe chronic plaque psoriasis.